MetaCap

Biodesix (BDSX) vs YD Bio (YDES)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biodesix (BDSX) has outperformed YD Bio (YDES) over the past year, gaining 10.7% versus a loss of 42.8%. YD Bio is the larger company by market cap ($342.1 million vs $83.8 million), about 4.1 times the size, while Biodesix is growing revenue faster (+24.1% vs +16.9%). Biodesix converts more of its revenue into profit, with a net margin of -39.8% versus -1392.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDSX+10.69%YDES-42.84%
+369%+135%-99%
Nov 21, 20251 yearNov 20, 2026
BDSX-11.48%YDES-61.36%
+258%+79%-101%
Aug 25, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDSX versus YDES key metrics
MetricBDSXYDES
Share price$7.56$4.83
Market cap$83.83M$342.12M
1-day change-8.92%+5.92%
YTD return+11.18%-60.38%
1-year return+10.69%-42.84%
5-year return-94.38%—
EPS (TTM)$-2.69$-0.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$88.50M$596.82K
Revenue growth (YoY)+24.08%+16.94%
Net income (latest FY)$-35.27M$-8.31M
Gross margin—28.05%
Operating margin-31.50%-883.31%
Net margin-39.85%-1392.61%
52-week high$31.97$15.72
52-week low$5.26$1.70
Distance from 52-week high-76.35%-69.27%
Analyst consensusstrong_buy—
Avg. price target upside+347.49%—
Average volume164.58K309.22K
Shares outstanding11.09M70.83M
Employees33413
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • YD Bio is about 4.1 times larger than Biodesix by market value ($342.12M vs $83.83M).
  • BDSX has outperformed YDES by 53.5 percentage points over the past year.
  • Biodesix is more profitable, keeping -39.8 cents of every revenue dollar as net income versus -1392.6 cents for YD Bio.
  • Biodesix grew revenue faster in its latest fiscal year (+24.08% vs +16.94%).

About Biodesix

BDSX stock →

Biodesix, Inc. operates as a diagnostic solutions company.

Health Care · Medical Specialities · 334 employees

About YD Bio

YDES stock →

YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.

Health Care · Medical Specialities · 13 employees

BDSX vs YDES FAQ

Which is bigger, Biodesix or YD Bio?

YD Bio (YDES) is larger, with a market capitalization of $342.12M compared with $83.83M for Biodesix (BDSX).

Which stock has performed better over the past year, BDSX or YDES?

BDSX returned +10.69% over the past 12 months, compared with -42.84% for YDES (price return, excluding dividends). Past performance does not predict future results.

Are Biodesix and YD Bio in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons